Trivitron Healthcare launches advanced diagnostic solutions for HbA1c based on HPLC technology
The products – NANO H5 and NANO H110 – will provide the result within 130 seconds
Trivitron Healthcare has launched two new products – NANO H5 and NANO H110 – for HbA1c- and Hb- variant detection. These products are High Performace Liquid Chromatography (HPLC) analysers for HbA1c detection in less than three minutes. These will be used for monitoring diabetes, thalassemia and haemoglobin variants, a company statement said.
The statement notified that NANO H5 is a compact and automated HPLC analyser that uses ion exchange liquid chromatography for the quantitative determination of the glycated haemoglobin (HbA1c) in human whole blood with a processing time of 130 seconds that will expedite the laboratory TAT. The fully automated analyser processes five samples at a time.
It also said that NANO H110 is a compact and automated HPLC analyser that has a dual test mode for HbA1c test and Hb-variant detection. It has some advanced facilities such as a barcode scanner and cap piercing with a high sample-loading capacity of 110 samples at a time which make it suitable for laboratories with medium to large workloads.
Speaking about the launch, Rajesh Patel, Chief Executive Officer – IVD Business, Trivitron Healthcare, said, “Keeping in mind the increasing concern for the management of diabetes and the growing demand for accurate measurement of HbA1c level, we are delighted to announce the launch of HPLC-based HbA1c analysers – NANO H5 and NANO H110, that are compact and designed for precision.”